Heron Therapeutics reports Q4 EPS 2c vs (7c) last year

Reports Q4 revenue $40.781M, consensus $37.37M. “2024 was a milestone year for Heron. We delivered strong financial results, including positive Net Income for Q4 2024, achieved our operational objectives, and repositioned the business for future growth. As we move into 2025, our product ZYNRELEF is poised for transformational growth, driven by its expanded label indications, the launch of the VAN, the approval of the NOPAIN Act, and the enhanced promotional reach of the Crosslink relationship,” said Craig Collard, Chief Executive Officer.